

Sunit Talapatra

Partner

stalapatra@foley.com

[Washington, D.C.](#)

202.295.4621



Dr. Sunit Talapatra's practice focuses on the intellectual property needs of diverse technology clients spanning pharmaceuticals, diagnostics, agriculture, food and nutrition, and medical devices. He also has a unique perspective on European companies with ties to the United States, having lived in the Netherlands and frequently returning to the continent. He is a partner in the firm's Chemical, Biotechnology & Pharmaceutical, and Private Equity & Venture Capital Practices as well as the Health Care & Life Sciences Sector.

In addition to patent counseling and prosecution matters, Sunit has argued several cases before the United States Patent Trial and Appeal Board, notably orchestrating a successful defense in the "1st-Ever" Pharma AIA Ruling (*Amneal Pharma Inc v. Supernus Pharma Inc.*). Some of his exemplary patent cases include *Chatterjee v. Tabor* (interference proceeding re DNA polymerase); *Keygene NV v. Floragenex, Inc.* (patent infringement action); and *Biota Scientific Ltd. v. Kappos* (appeal of USPTO decision re obviousness of pharmaceutical formulation).

Awards and Recognition

- Recognized in *IAM Patent 1000 – The World's Leading Patent Practitioners* (2024)

Presentations and Publications

- "General Counsel Speak: Building a Forward-Thinking IP Strategy," Foley's Annual IP Conference (October 2022)
- "Perspectives on the New Normal," Foley's Annual IP Conference (October 2021)
- "Patenting Strategies: The Counsel (Corporate and Private)," FCBA Global Outreach Series (October 2016)
- "IP Management: Getting It Right in Both Europe and the US," Innovation for Health Conference (February 2014)

- “Legal Issues Facing Health Companies in the US Market,” Health & Technology Conference (September 2013)
- “Hindsight is 20/20: Entrepreneurs Share Viewpoints on What They Wish They’d Known,” Nanotech Commercialization Conference (April 2013)
- “Intellectual Property,” Wharton Business Law Conference (February 2013)
- “Intellectual Property Life Cycle Management—Thoughts to Consider in Strategic Patent Protection,” American Chemical Society (August 2012)
- “Risk vs Value: The Impact of Nanotechnology Environmental Health Safety (EHS) on Business Decisions,” Nanotech Commercialization Conference (April 2012)
- “What’s ‘natural’ about natural resources? Implications for your IP,” American Chemical Society (March 2011)
- Talapatra S, Bent S, The Art of Negotiating with U.S. Patent Examiners, A.I.P.P.I. 56(2), (2011)
- “Negotiating a patent: the art of Examiner interviews,” American Chemical Society (August 2010)
- Talapatra S, Thompson CB, et al., Elongation Factor-1 alpha Is a Selective Regulator of Growth Factor Withdrawal and ER Stress- induced Apoptosis, *Cell Death Differ.*, 9(8), 2002, 856-61
- Karnauskas R, Talapatra S, and Rudin C, et al., Bcl-xL and Akt Cooperate to Promote Leukemogenesis In Vivo, *Oncogene*, 22(5), 2003, 688-98

Thought Leadership

Sunit has authored several legal and scientific publications and is frequently quoted in *FDA Week* and *Inside Health Policy*. He also regularly lectures on patent matters, most recently at the 2016 FCBA Global Outreach Series (Paris).

Sectors

- [Racial Justice & Equity](#)

Practice Areas

- [Chemical, Biotechnology & Pharmaceutical](#)
- [Intellectual Property](#)
- [Private Equity](#)
- [Transactions](#)

Education

- The George Washington University (J.D.)
- University of Pennsylvania (Ph.D.)
 - Cell and Molecular Biology
- University of Chicago (M.S.)
 - Biochemistry
 - Molecular Biology
- University of California at Los Angeles (B.S.)

- Chemistry
- Graduate work in cancer biology was conducted under the guidance of Dr. Craig Thompson

Admissions

- Virginia
- District of Columbia
- U.S. Patent and Trademark Office